Philadelphia, PANCT05140148Now EnrollingIRB Ready

Stroke, Ischemic Clinical Trial in Philadelphia, PA

Access cutting-edge stroke, ischemic treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by University of Pennsylvania

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access stroke, ischemic specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related stroke, ischemic treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this stroke, ischemic clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Stroke, Ischemic Study in Philadelphia

The investigators aim to examine whether amantadine can help patients recover from stroke. This will be a blinded randomized clinical trial (RCT). Patients will be randomized post-ischemic or hemorrhagic stroke either to the placebo arm or amantadine arm. Patients will be on study drug or placebo for 1 month but will be enrolled for 3 months total. At various time points patients will be examined and fill out questionnaires to determine level of stroke recovery.

Sponsor: University of Pennsylvania

Who Can Participate

Inclusion Criteria

18 to 85 years old, male and female
Modified Rankin Score (mRS)\<=2 prior to stroke
Ischemic or hemorrhagic stroke as diagnosed by vascular neurologist or as proven on magnetic resonance imaging (MRI) or non-contrast head computed tomography NCHCT)
24 hours to 3 weeks after stroke onset or time last known well prior to detection of symptoms
National Institute of Health Stroke Scale (NIHSS)\>=3 and NIHSS\<=15
Creatinine Clearance of greater than or equal to 60 mL/min using the Cockroft- Gault equation.
Have passed a swallow evaluation prior to drug administration
The patient is an acute rehabilitation candidate or candidate for the Homeward Stroke Program
Able to participate in administered tests

Exclusion Criteria

Any degree of receptive aphasia
Moderate or severe expressive aphasia
Currently pregnant or plans to get pregnant
Currently breastfeeding
Any patient admitted with primary SubarachnoidH emorrhage (SAH )on either non-contrast head CT or MRI brain
Diagnosis of dementia or mild cognitive impairment prior to index stroke
Prior limb amputation
Currently prescribed or taking a primary anticholinergic medication
Currently enrolled in any other investigational pharmacologic or procedural clinical trial
Malignancy with active treatment
History of prior stroke with residual impairment
Current or prior neuroleptic use
History of suicidality or psychosis (The Columbia Suicide Severity Ratings Scale (C-SSRS) will be administered at the screening visit to assess depression and suicidal thoughts for subject eligibility. Any subjects who indicate severe depression or suicidal thoughts and/or attempts within the last year will not be eligible)
Prior history of seizures
Prior treatment with amantadine
Parkinson's disease
Amantadine allergy
Elevated liver function tests (aspartate aminotransferase and alanine aminotransferase above the upper limit of normal) -

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT05140148) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Stroke, Ischemic Treatment Options in Philadelphia, PA

If you're searching for stroke, ischemic treatment options in Philadelphia, PA, this clinical trial (NCT05140148) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stroke, ischemic specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all stroke, ischemic clinical trials near you to find additional studies recruiting in your area.

More Stroke Trials in Philadelphia, PA

See all stroke clinical trials recruiting in Philadelphia — not just this study.

Browse Stroke Trials in Philadelphia →

Browse More Trials by Condition

Stroke TrialsHeart Attack TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA